Form 4: Theravance Biopharma SVP Reports Routine Share Withholding

Rhonda Farnum, SVP of Commercial and Medical Affairs at Theravance Biopharma, Inc., reported a routine disposition of shares to cover tax obligations related to vested restricted stock units.

Summary

• Rhonda Farnum, SVP, Commercial and Medical Affairs at Theravance Biopharma, Inc. (TBPH), reported a transaction on February 20, 2026.
• The transaction involved the disposition of 13,929 Ordinary Shares at a price of $19.66 per share.
• These shares were withheld by the issuer to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• This was not an open market transaction.
• Following this transaction, Ms. Farnum beneficially owns 263,766 Ordinary Shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a standard, non-discretionary transaction related to executive compensation and does not indicate any change in company fundamentals or management's sentiment.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as share withholdings for tax purposes, are common in the biotechnology and pharmaceutical sectors as part of executive compensation plans. These transactions typically do not reflect a change in management's outlook on the company's fundamentals or future prospects.

Comparison to Industry Standards

• Share withholding for tax purposes upon RSU vesting is a standard practice across publicly traded companies, including those in the biotech industry, such as Amgen, Gilead Sciences, and Biogen. The volume of shares disposed by Ms. Farnum is consistent with typical executive compensation structures for a Senior Vice President role in a company of Theravance Biopharma's size.

Related Party Transactions

• The share withholding transaction was with the issuer (Theravance Biopharma, Inc.) and did not involve an open market transaction, which is a common form of related party transaction for tax purposes.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in insider sentiment or company performance.
• Employees: Reinforces the standard practice of equity compensation and tax handling for vested awards.

Key Dates

Keywords

Theravance Biopharma, TBPH, Rhonda Farnum, SEC Form 4, Insider Transaction, Share Withholding, Restricted Stock Units, Tax Obligations